56% og 85% hos forsøgspersoner med moderat og svært nedsat leverfunktion.
Systemic exposure (AUC) to lapatinib after a single oral 100 mg dose increased approximately 56% and 85% in subjects with moderate and severe hepatic impairment, respectively.